Biogen Statistics
Share Statistics
Biogen has 145.72M shares outstanding. The number of shares has increased by 0.25% in one year.
| Shares Outstanding | 145.72M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.04% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 144.68M |
| Failed to Deliver (FTD) Shares | 6.07K |
| FTD / Avg. Volume | 0.41% |
Short Selling Information
The latest short interest is 2.58M, so 1.77% of the outstanding shares have been sold short.
| Short Interest | 2.58M |
| Short % of Shares Out | 1.77% |
| Short % of Float | 1.78% |
| Short Ratio (days to cover) | 1.67 |
Valuation Ratios
The PE ratio is 32.25 and the forward PE ratio is 10.1. Biogen 's PEG ratio is 0.14.
| PE Ratio | 32.25 |
| Forward PE | 10.1 |
| PS Ratio | 3.81 |
| Forward PS | 2.2 |
| PB Ratio | 2.53 |
| P/FCF Ratio | 30.3 |
| PEG Ratio | 0.14 |
Enterprise Valuation
Biogen Inc. has an Enterprise Value (EV) of 43.73B.
| EV / Earnings | 37.66 |
| EV / Sales | 4.45 |
| EV / EBITDA | 18.4 |
| EV / EBIT | 20.85 |
| EV / FCF | 35.39 |
Financial Position
The company has a current ratio of 2, with a Debt / Equity ratio of 0.47.
| Current Ratio | 2 |
| Quick Ratio | 1.26 |
| Debt / Equity | 0.47 |
| Total Debt / Capitalization | 31.92 |
| Cash Flow / Debt | 0.22 |
| Interest Coverage | 8.49 |
Financial Efficiency
Return on equity (ROE) is 0.08% and return on capital (ROIC) is 8.49%.
| Return on Equity (ROE) | 0.08% |
| Return on Assets (ROA) | 0.04% |
| Return on Capital (ROIC) | 8.49% |
| Revenue Per Employee | 1.30M |
| Profits Per Employee | 153.38K |
| Employee Count | 7.57K |
| Asset Turnover | 0.37 |
| Inventory Turnover | 1 |
Taxes
| Income Tax | 135.30M |
| Effective Tax Rate | 0.1 |
Stock Price Statistics
The stock price has increased by -41.91% in the last 52 weeks. The beta is -0.06, so Biogen 's price volatility has been lower than the market average.
| Beta | -0.06 |
| 52-Week Price Change | -41.91% |
| 50-Day Moving Average | 157.95 |
| 200-Day Moving Average | 196.46 |
| Relative Strength Index (RSI) | 31.71 |
| Average Volume (20 Days) | 1.50M |
Income Statement
In the last 12 months, Biogen had revenue of 9.84B and earned 1.16B in profits. Earnings per share was 8.02.
| Revenue | 9.84B |
| Gross Profit | 7.30B |
| Operating Income | 2.10B |
| Net Income | 1.16B |
| EBITDA | 2.38B |
| EBIT | 2.10B |
| Earnings Per Share (EPS) | 8.02 |
Balance Sheet
The company has 1.05B in cash and 7.34B in debt, giving a net cash position of -6.29B.
| Cash & Cash Equivalents | 1.05B |
| Total Debt | 7.34B |
| Net Cash | -6.29B |
| Retained Earnings | 17.63B |
| Total Assets | 28.31B |
| Working Capital | 1.41B |
Cash Flow
In the last 12 months, operating cash flow was 1.55B and capital expenditures -311.40M, giving a free cash flow of 1.24B.
| Operating Cash Flow | 1.55B |
| Capital Expenditures | -311.40M |
| Free Cash Flow | 1.24B |
| FCF Per Share | 8.54 |
Margins
Gross margin is 74.24%, with operating and profit margins of 21.32% and 11.81%.
| Gross Margin | 74.24% |
| Operating Margin | 21.32% |
| Pretax Margin | 13.18% |
| Profit Margin | 11.81% |
| EBITDA Margin | 24.17% |
| EBIT Margin | 21.32% |
| FCF Margin | 12.56% |
Dividends & Yields
BIIB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 5.61% |
| FCF Yield | 5.93% |
Analyst Forecast
The average price target for BIIB is $210, which is 46.9% higher than the current price. The consensus rating is "Hold".
| Price Target | $210 |
| Price Target Difference | 46.9% |
| Analyst Consensus | Hold |
| Analyst Count | 25 |
Stock Splits
The last stock split was on Jan 18, 2001. It was a forward split with a ratio of 3:1.
| Last Split Date | Jan 18, 2001 |
| Split Type | forward |
| Split Ratio | 3:1 |
Scores
| Altman Z-Score | 2.72 |
| Piotroski F-Score | 6 |